AMRS - Amyris, Inc.
Pre-Market:
| Previous Close | 0.7518 |
| Open | 0.7500 |
| Bid | 0.8401 x 1000 |
| Ask | 0.8420 x 1000 |
| Day's Range | 0.7301 - 0.8450 |
| 52 Week Range | 0.5500 - 4.8600 |
| Volume | |
| Avg. Volume | 4,707,852 |
| Market Cap | 311.614M |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0200 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.68 |
ZacksAmyris (AMRS) Q1 Earnings In Line, Revenues Beat Estimates
Amyris (AMRS) sees lower sales in its Consumer and Technology Access segments in the first quarter.
Simply Wall St.Individual investors account for 38% of Amyris, Inc.'s (NASDAQ:AMRS) ownership, while institutions account for 31%
Key Insights Amyris' significant individual investors ownership suggests that the key decisions are influenced by...
ZacksAmyris, Inc. (AMRS) Reports Q1 Loss, Tops Revenue Estimates
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAnalysts Estimate Mativ Holdings (MATV) to Report a Decline in Earnings: What to Look Out for
Mativ Holdings (MATV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Amyris, Inc. (AMRS) Expected to Beat Earnings Estimates: Should You Buy?
Amyris, Inc. (AMRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Not Many Are Piling Into Amyris, Inc. (NASDAQ:AMRS) Just Yet
There wouldn't be many who think Amyris, Inc.'s ( NASDAQ:AMRS ) price-to-sales (or "P/S") ratio of 1.3x is worth a...
ZacksAmyris (AMRS) and Givaudan Close Cosmetic Ingredients Deal
Amyris (AMRS) and Givaudan collaborate to leverage the former's technological platform for designing, scaling and manufacturing the best-performing bio-fermented ingredients.
- Simply Wall St.
Are Amyris, Inc. (NASDAQ:AMRS) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amyris fair value estimate is US$1.07 Amyris is estimated to...
- Simply Wall St.
Is Now The Time To Look At Buying Amyris, Inc. (NASDAQ:AMRS)?
While Amyris, Inc. ( NASDAQ:AMRS ) might not be the most widely known stock at the moment, it saw a decent share price...
- Simply Wall St.
Amyris Full Year 2022 Earnings: Misses Expectations
Amyris ( NASDAQ:AMRS ) Full Year 2022 Results Key Financial Results Revenue: US$269.8m (down 21% from FY 2021). Net...
ZacksAmyris (AMRS) Q4 Earnings and Revenues Lag Estimates
Record revenues in the Consumer segment drive Amyris' (AMRS) top line in the fourth quarter.
ZacksAmyris, Inc. (AMRS) Reports Q4 Loss, Misses Revenue Estimates
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -160% and 27.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Shareholders in Amyris (NASDAQ:AMRS) have lost 68%, as stock drops 12% this past week
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
- Simply Wall St.
Bullish Amyris, Inc. (NASDAQ:AMRS) insiders filled their treasuries with US$20m worth of stock over last year
Multiple insiders secured a larger position in Amyris, Inc. ( NASDAQ:AMRS ) shares over the last 12 months. This is...
- Simply Wall St.
Institutional investors may adopt severe steps after Amyris, Inc.'s (NASDAQ:AMRS) latest 10% drop adds to a year losses
Every investor in Amyris, Inc. ( NASDAQ:AMRS ) should be aware of the most powerful shareholder groups. The group...
Motley FoolWhy Amyris Stock Was Driven Into the Ground on Wednesday
Synthetic-biology company Amyris (NASDAQ: AMRS) had an absolutely awful day on the stock exchange Wednesday, due to an earnings report that fell well short of expectations. After market hours on Tuesday, Amyris divulged its third-quarter results. Alas, the total fell far short of the average analyst estimate of just under $112 million.
ZacksAmyris, Inc. (AMRS) Reports Q3 Loss, Misses Revenue Estimates
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -109.52% and 36.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Motley FoolWhy Amyris Stock Tumbled This Week
Amyris had a good news/bad news Tuesday, with the market deciding that the latter outweighed the former. The good was that three of the specialized biotech company's products will be included in the offerings of Sephora when the big cosmetics retailer launches its U.K. website. While having three out of the undoubtedly many Sephora products on the site isn't considerable and thus won't generate monster sales, being in that selection is indisputably a positive development for Amyris.
- Simply Wall St.
Is Now An Opportune Moment To Examine Amyris, Inc. (NASDAQ:AMRS)?
While Amyris, Inc. ( NASDAQ:AMRS ) might not be the most widely known stock at the moment, it led the NASDAQGS gainers...
- Simply Wall St.
Are Investors Undervaluing Amyris, Inc. (NASDAQ:AMRS) By 41%?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Amyris, Inc...
Motley Fool3 Stocks That Can Double Your Money According to Wall Street
Analysts working at Wall Street investment banks have some stocks in mind that have fallen on hard times but still have a chance to succeed. Ginkgo Bioworks (NYSE: DNA) and its mission to do fun stuff with DNA excited early investors in 2021. Unfortunately, the company manages custom-built organisms much better than it handles its cash flows.
- Simply Wall St.
Amyris, Inc. (NASDAQ:AMRS) Just Reported Earnings, And Analysts Cut Their Target Price
As you might know, Amyris, Inc. ( NASDAQ:AMRS ) last week released its latest quarterly, and things did not turn out so...
Motley FoolAmyris (AMRS) Q2 2022 Earnings Call Transcript
This call is being webcast live on the events page of the investor section of the Amyris' website at amyris.com. You may listen to a webcast replay of this call by going to the investor section of Amyris' website. With me on today's call are John Melo, president and chief executive officer; and also Eduardo Alvarez, chief operating officer to support our Q&A session today.
ZacksAmyris, Inc. (AMRS) Reports Q2 Loss, Lags Revenue Estimates
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -50% and 20.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
